18 Papers
218 Citations
Wei He is an academic researcher from Johnson & Johnson Pharmaceutical Research and Development. The author has contributed to research in topics: Opioid receptor & Receptor. The author has an hindex of 10, co-authored 18 publications. Previous affiliations of Wei He include Johnson & Johnson.
Chat about Author
Papers
Patent
Novel compounds as opioid receptor modulators
Henry J. Breslin,Chaozhong Cai,Wei He,Kavash Robert W +3 more
- 14 Mar 2005
TL;DR: In this article, the authors present methods for preparing such compounds, pharmaceutical compositions containing them, and their use in the treatment of disorders that may be ameliorated or treated by the modulation of opioid receptors.
52
Identification of a dual δ OR antagonist/μ OR agonist as a potential therapeutic for diarrhea-predominant Irritable Bowel Syndrome (IBS-d)
Henry J. Breslin,Craig J. Diamond,Kavash Robert W,Chaozhong Cai,Alexey B. Dyatkin,Tamara A. Miskowski,Sui-Po Zhang,Paul R. Wade,Pamela J. Hornby,Wei He +9 more
TL;DR: Compound 5l has progressed through a clinical Phase II Proof of Concept study on 800 patients suffering from diarrhea-predominant Irritable Bowel Syndrome (IBS-d), with 5l demonstrating statistically significant efficacy over placebo.
51
Patent
Aza-bridged-bicyclic amino acid derivatives as .alpha.4 integrin antagonists
Alexey B. Dyatkin,Bruce E. Maryanoff,Hoekstra William J,Wei He,William A. Kinney +4 more
- 29 Jun 2001
TL;DR: In this paper, aza-bridged-bicyclic compounds having Formula (I): Formula(I) and pharmaceutically acceptable salts thereof are presented. The compounds are useful α4 integrin receptor antagonists and, in particular, α4 β1 and α4β7 integrin receptors antagonists.
30
Patent
Prokineticin 2 receptor antagonists
Steven J. Coats,Alexey B. Dyatkin,Wei He,Joseph G. Lisko,Tamara A. Miskowski,Janet L. Ralbovsky,Mark Schulz +6 more
- 28 Dec 2006
TL;DR: In this article, the authors present methods for the treatment of prokineticin 2 or prokinetin 2 receptor mediated disorders. But the present method is not suitable for certain novel compounds of Formula (I):
29
Rationale, design, and synthesis of novel phenyl imidazoles as opioid receptor agonists for gastrointestinal disorders.
Henry J. Breslin,Tamara A. Miskowski,Bryan M. Rafferty,Santosh V. Coutinho,Jeffrey M. Palmer,N. H. Wallace,Craig R. Schneider,Edward S. Kimball,Sui-Po Zhang,Jian Li,Raymond W. Colburn,Dennis J. Stone,Rebecca P. Martinez,Wei He +13 more
TL;DR: In vivo results suggest that imidazole 4a acts peripherally when dosed systemically, and that these prototypical compounds may prove promising as medicinal leads for GI indications.
26